Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.1828
+0.00030.16%
Post-market: 0.18450.0017+0.93%16:12 EDT
Volume:532.17K
Turnover:98.02K
Market Cap:7.29M
PE:-0.05
High:0.1870
Open:0.1820
Low:0.1810
Close:0.1825
52wk High:2.88
52wk Low:0.1659
Shares:39.89M
Float Shares:37.90M
Volume Ratio:0.54
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.94
PE(LYR):-0.01

Loading ...

AIM ImmunoTech Highlights Duripanc Trial Testing Ampligen Plus AstraZeneca’s Imfinzi in Metastatic Pancreatic Cancer Maintenance Therapy

Reuters
·
Yesterday

AIM ImmunoTech Says Phase 2 Duripanc Pancreatic Cancer Trial Advances Toward Q1 2027 Topline Data

Reuters
·
Oct 01

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as Duripanc Advances Toward Topline Data

THOMSON REUTERS
·
Oct 01

AIM ImmunoTech Expects Q1 2027 Topline Data from Phase 2 Duripanc Trial of Ampligen Plus Durvalumab in Metastatic Pancreatic Cancer

Reuters
·
Sep 30

AIM ImmunoTech Targets Q1 2027 Topline Data for Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer

Reuters
·
Sep 22

AIM ImmunoTech CEO Thomas K Equels Acquires Common Shares Worth $4,992

Reuters
·
Sep 18

AIM ImmunoTech CEO Thomas K. Equels Acquires $4,862 Common Shares

Reuters
·
Sep 16

AIM ImmunoTech Issues 1,921,441 Shares in $450,000 Debt Exchange with Streeterville Capital

Reuters
·
Sep 11

AIM ImmunoTech Advances Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer

Reuters
·
Sep 09

AIM ImmunoTech Issues 5,065,840 Shares in Unregistered Note Exchange with Streeterville Capital

Reuters
·
Sep 05

AIM ImmunoTech Expands Ampligen Long COVID Patent Protection Across Europe, UK Through 2041

Reuters
·
Sep 02

AIM ImmunoTech Wins U.S. Patent Covering Ampligen-Keytruda Combo Cancer Therapy Through 2039

Reuters
·
Aug 31

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology Ip Protection for Ampligen Through 2039

THOMSON REUTERS
·
Aug 31

Morgans Sticks to Their Hold Rating for Ai-Media Technologies Limited (AIM)

TIPRANKS
·
Aug 28

Boku Tightens Free Float With Latest Share Buyback on AIM

TIPRANKS
·
Aug 27

Windar Photonics Directors Deepen Commitment in AIM Fundraise

TIPRANKS
·
Aug 27

Hargreave Hale AIM VCT Tightens Share Base with Buyback and Cancellation

TIPRANKS
·
Aug 26

PetroTal Non‑Executive Director Boosts Stake With AIM Share Purchase

TIPRANKS
·
Aug 26

Oxford BioDynamics Wins Shareholder Backing for Massive AIM Placing

TIPRANKS
·
Aug 26

Windar Photonics launches £4m equity raise amid accounting probe and AIM suspension

TIPRANKS
·
Aug 24